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ABSTRACT 
 Osteoarthritis (OA) is a degenerative joint disease that affects an estimated 9.6 % of men 
and 18 % of women over 60 years of age.  However, there is no chondroprotective agent 
that is approved for clinical application. We showed that LOXL2 is elevated in the 
regenerative response during fracture healing in mice and has a critical role in 
chondrogenic differentiation. Indeed, LOXL2 is an anabolic effector that attenuates pro-
inflammatory signaling in OA cartilage of the TMJ and knee joint, induces 
chondroprotective and regenerative responses. The goal of the present study was to 
evaluate if LOXL2 adenovirus in vivo promotes protective and anabolic responses in the 
knee and TMJ-OA cartilage. We employed (Cho/+) OA mouse model to assess knee and 
TMJ-OA, which is a genetic model that develops progressive TMJ-OA due to a mutation 
in the Col11a1 gene. Intraperitoneal injection every 2 weeks of Adv-RFP-LOXL2 in four-
month-old Cho/+ male and female mice for 16 weeks upregulated Sox9, aggrecan (Acan) 
and other anabolic genes in the knee and TMJ. Next, to evaluate if LOXL2 expression 
occurred in degenerative lesions in human clinical TMJ-OA, immunofluorescence and 
confocal image analysis were performed. LOXL2 has the potential to induce anabolic gene 
		 iv 
expression in the progressive knee and TMJ-OA mouse model. We showed for the first 
time that LOXL2-related functions could be useful for anabolic therapies for Cho/+ mice 
progressive knee and TMJ-OA.  Thus, these data show that LOXL2 could have clinical 
translational applications in the future for OA-related anabolic therapies. 
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INTRODUCTION  
Osteoarthritis (OA) is a degenerative joint disease that affects an estimated 9.6% of men 
and 18% of women over 60 years of age. It is classified as one of the top ten most 
disabling diseases by the World Health Organization. Despite OA high prevalence, no 
therapy to prevent or repair joint degeneration is available. Surgical interpretation is 
required in severe cases. Although the exact cause for OA is unknown, multiple risk 
factors contribute to OA. These risk factors include genetics, aging, obesity and 
mechanical factors.[1]  
Major changes that lead to irreversible, progressive OA include alteration to the 
composition and structure of the extracellular matrix (ECM) that changes biological and 
mechanical microenvironments, and defective ECM remodeling. Another key factor is 
the loss of chondrocytes due to apoptosis.[2, 3]  
Lysyl oxidase (LOX) family members including LOX, LOXL1, LOXL2, LOXL3 and 
LOXL4 are copper-dependent amine oxidases. The primary difference between these 
amine oxidases was found in their N-terminal sequence, which contributes to their 
functions. The LOX family has an important role in ECM remodeling and collagen cross-
linking. Moreover, LOX is critical for structural stability and function of bone since 
collagen type I is the main component in the extracellular bone matrix. Therefore, the risk 
of bone deformations and fractures could increase due to reduced LOX enzyme activity.[4]  
It is shown that LOXL2 levels increased during the fracture healing process in mice, and 
that it helps in chondrocyte differentiation and maintenance of cartilage ECM.[5, 6]  
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However, the exact anabolic role of LOXL2 during the OA disease process is not 
currently understood. Preliminary results in our lab showed that LOXL2 was observed in 
damaged parts of cartilage near bone cysts, compared to the insignificant levels of 
LOXL2 in the healthy regions of tissues using immunofluorescence and 
immunohistochemistry performed on the human knee and TM joints. Thus, LOXL2 
levels are increased in damaged joints. Earlier published study by Dr. Bais lab by 
Alshenibr et al[20] showed that LOXL2 gene expression can be affected by important 
factors affecting OA-related processes in cartilage. LOXL2 mRNA levels in human 
articular chondrocytes (HAC-OA) were reduced by TNF-α, and IL-1β. While, levels 
were upregulated by TGF-β1 compared to vehicle. Moreover, it was examined if LOXL2 
promotes the differentiated chondrocyte phenotype, by evaluating proliferation, 
chondrocyte phenotypic markers, and TNF- α and IL-1β-induced effects on COL2A1 
mRNA and apoptosis using chondrocytes isolated from healthy cartilage (HAC-N) or OA 
cartilage (HAC-OA) and transduced with viral vectors. Alshenibr et al[20] found that 
LOXL2 promotes the differentiated chondrocyte phenotype and inhibits apoptosis in 
human chondrocytes from OA cartilage. Also, To determine the results of LOXL2 
overexpression on potential OA-related targets, global gene expression analysis on total 
RNA extracted from HAC-OA after transduction with Ad-RFP-LOXL2 or Ad-RFP-
Empty was done. Inducing LOXL2 differentially affects genes in OA chondrocytes. It is 
also found that specific gene sets were regulated by LOXL2. 
OA studies have relied on animal models, since obtaining cartilage biopsies from human 
joints is considered unethical.[7]  The animal model should be a group of homogenous 
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animals with a biological process that mimics the disease in humans in one or more 
aspects. This biological process could be inherited, naturally acquired or experimentally 
initiated.[8] Mice have many characteristics that made them good experimental animals. 
Mice are small in size and easy to handle. Moreover, their life span is 2-3 years with a 
good breeding capability. OA research has relied on gene-mutated mice as experimental 
animals due to the development in transgenic technology. The term ‘transgenic’ here 
means that there is a new genetic material has been added to the animal germ line.[9] This 
can be achieved by injecting the DNA into one pronucleus of the fertilized egg.[10]  Then 
the egg is shifted to a foster-mother. Offspring carrying the transgene are examined using 
polymerase chain reaction or Southern blot. When mice carrying the transgene are bred 
with wild-type or transgenic mice, the offspring will be heterozygous (HT) or 
homozygous (HM) for the transgene, or wild-type (WILD). 
Chondrodysplasia ( Cho/+) mice is a good model to study progressive OA changes. The 
loss of α1(XI) collagen chains in cartilage is related to Autosomal recessive 
chondrodysplasia in mice (Cho). This loss consequences from a single-nucleotide 
deletion in the Col11a1 gene, result in a frame shift and premature termination of 
translation. The minor component of collagen fibrils in cartilage called Type XI collagen. 
It is a heterotrimer constituted of a1(XI), a2(XI) and a3(XI) collagen chains. In the 
cartilage of Cho mice, the mutation results in the presence of abnormally thick collagen 
fibrils and elevated extractability of proteoglycans from the cartilage. Different 
abnormalities are found in the cartilage of homozygous mice. These abnormalities affect 
the ribs, limbs, mandible and trachea. Moreover, breathing difficulties due to these 
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abnormalities can lead to mice death at birth.[11] On the other hand, OA- like changes in 
the joints appeared several months earlier during aging than they appear in control 
animals.[9, 10] Variation in organization and number of chondrocytes is considered as 
major morphological OA change. Other changes include variations in the staining of the 
matrix and the extent of fibrillogenesis. 
The phenotype of these mice is caused by haploinsufficiency of collagen a1(XI) which is 
caused by the recessive Cho mutation.[10] The progressive changes in Cho/+ mice at 
articular cartilage was displayed histologically.[12]  At the age of 1 month, no differences 
between Cho/+ and wild type mice were mentioned in the joints. At age 3 months, a 
smaller number of chondrocyte clusters was observed in the superficial layer of articular 
cartilage of the wild-type controls compared to Cho/+ mice. The chondrocyte clusters 
were detected in different areas in the articular cartilage from Cho/+ mice. However, no 
significant difference between the knee joints of Cho/+ and wild-type mice was 
recognized at 3 months of age. 
At age 6 months, loss of proteoglycan staining at the superficial zones in Cho/+ mice was 
clear. At 9 months, the region of deficient staining extended from the superficial to the 
deep layers and by 15 months of age, Cho/+ mice revealed typical OA-like knee joints, 
including loss of articular cartilage, misshaped meniscus, and inflammation in the 
synovial tissues compared with that of articular cartilage from the normal littermates. 
Similar histological analysis was done on the temporomandibular joint (TMJ). At the age 
of 1 month, there was no significant difference between the TM joints from Cho/+ and 
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wild-type mice. While at age 3 months the proteoglycans are more diffused with a 
distribution over the whole layer of articular cartilage of TM joints from Cho/+ mice. 
In contrast, the proteoglycans are localized mainly in the deep zone of wild-type articular 
cartilage. Severe OA-like changes were mentioned at the age of 6 months. These changes 
are flattening of the condylar head, loss of proteoglycans, and a reduced hypertrophic 
zone. At age 9 months, fibrillations that perforated the whole articular cartilage were 
there in the TM joints from Cho/+ mice. 
Immunohistochemistry analysis showed that at 3 months MMP-3 expression and at 6 
months MMP-13 was higher in knee joints from Cho/+ mice than in joints from their wild-
type littermates.[12] LOXL2 is an ideal candidate to be evaluated in Cho/+ model because 
LOXL2 promotes chondrogenic differentiation, biosynthesis of collagen and 
proteoglycans collagen crosslinking enzyme which has the ability to protect from OA.  
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Hypothesis:  
LOXL2 has a specific anabolic function in progressive TMJ and knee joint osteoarthritis 
in vivo.  
 
Aim: 
The aim of the study is to evaluate the role of LOXL2 in CHO/+ mice with progressive 
TMJ and knee OA articular cartilage by mRNA expression and proteoglycan staining. 
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METHODS  
Preparation of adenovirus: Adenoviruses for LOXL2 expression (Ad-CMV-RFP-
CMV-hLOXL2-His; referred to as Ad-RFP-LOXL2), and the empty vector control (Ad-
RFP-Empty) were custom synthesized (ADV-214438) by Vector BioLabs, PA. These 
adenovirus particles were amplified in 293T cells and quantified using an adenovirus 
quantification kit (Cell Biolabs). The expression of LOXL2 protein was evaluated by 
Western blotting of the media and cell layer, and enzymatic activity of purified LOXL2 
was evaluated by the Amplex Red assay[13, 14]. 
 
Cho-OA(+ve) mice model: Total number of Cho-OA(+ve) mice was 27 mice divided 
into 14 males and 13 females. These males and females were divided into 7 males and 7 
females injected with Ad-LOXL2 and 7 males and 6 females injected with Ad-empty. 
These mice were injected intraperitoneally every week for 16 weeks. Adenoviruses for 
expression of  
LOXL2 (Ad-CMV-RFP-CMV-hLOXL2-His; referred to as Ad-RFP-LOXL2), and its 
empty vector control (Ad-RFP-Empty) were custom manufactured (ADV-214438) by 
Vector Biolabs, PA. 293T cells were used for adenovirus amplifications. This was done 
under BL2 conditions. Knee and TMJ condylar cartilage were harvested and subjected to 
total RNA extraction, RT-qPCR and histology analysis.
	8 
 
 
 
 
Use of human tissues and animal experiments: Human tissue samples were collected 
with informed consent and experiments were conducted in accordance with relevant 
guidelines and regulations of Boston University Institutional Review Board (IRB; approval 
number H33300). All mouse experiments were performed with guidance, regulations, and 
approval of Boston University Institutional Animal Care and Use Committee (IACUC; 
approval number AN-15387.  
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RNA isolation and analysis: RNeasy mini kit (Qiagen) was used for RNA isolation. 
RNA quantification was done using ND-1000 Spectrophotometer and ND-1000 V3.1.2 
software. High-Capacity cDNA Reverse Transcription kit from Applied Biosystems was 
used to make the cDNA. Reverse transcription was done under the following setup 25C 
for 10 minutes, 37C for 120 minutes, 85C for 5 minutes, 4C for 10 minutes, using Gene 
Amp PCR system 9700 (Applied Biosystems).  RT-PCR reactions were done using 
standard 96 well plate, cDNA, master mix and and different probes viewed in the 
following table (Table 1). RT-PCR reactions were done using Applied Biosystems. 
 
 
Gene Catalogue number 
GAPDH Mm 99999915_g1 
LOXL2 Mm 00804740_m1 
RUNX2 Mm 00501578_m1 
VEGFB Mm 00442102_m1 
MMP13 Mm 01168713_m1 
SOX9 Mm 00448840_m1 
ACANN Mm 00545794_m1 
COL2A1 Mm 00491889_m1 
RANKL Mm 00441908_m1 
  
Table 1: Probes used in RT-PCR 
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Confocal imaging and immunofluorescence analysis: Paraffin-embedded tissue sections 
were labeled with mouse SOX9 antibody (Abcam; ab76997) or its isotype control (Vector 
Biolabs) detected with anti-mouse IgG conjugated to Alexa 488. To detect LOXL2 
expression, the tissues were incubated with rabbit anti-LOXL2 (GeneTex, Inc) or its 
isotype control antibody and detected with anti-rabbit biotin antibody followed by 
streptavidin-conjugated Texas red. Anti-fade reagent with DAPI was added to all samples 
before imaging. A Zeiss 710 dual scanner confocal microscope with a Plan-Apochromat 
objective, oil immersion lens and a CCD detector was used to obtain confocal images. 
Image acquisition was performed with Zeiss Zen image analysis software (Carl Zeiss 
Micro Imaging, Inc., Thornwood, NY). Image analysis was performed using Zeiss LSM 
viewer and Image J software (NIH, USA). Z-stack image analysis and 3-dimensional 
reconstruction were performed using LOCI and the Image J software 3D viewer plug-in.  
 
Safranin O Staining: A) Deparaffinization was performed with 2 changes of Xylene, 5 
minutes for each change. B) Rinsing with absolute Alcohol for 3 changes, 1 minute for 
each change. C) Rinsing with tap water for 1 minute. D) Weigert’s Hematoxylin A and 
Weigert’s Hematoxylin B were mixed with 1/1 ratio and the slides were immersed in the 
mixture for 5 minutes then rinsed with running tap water for 1 minute. E) Slides were 
immersed in 0.2% fast green for 5 minutes then immersed in 1% Acetic acid for 15 
seconds. F) Immersion in 1% Safranin O for 5 minutes. G) Dehydration was done using 3 
changes of absolute Alcohol, each change for 1 minute. H) Slides were cleared with 3 
changes of Xylene, each change for 1 minute. I) Covering the slides was done using 
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Permount mounting media from Fisher Scientific. Safranin O stain kit from American 
MasterTech was used for the whole procedure. 
 
Data analyses were accomplished using two way ANOVA with Bonferroni post-hoc 
analysis or Student's t-test (Graph Pad Prism 5 software). 	
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RESULTS 
LOXL2 regulates anabolic genes in the Knee and TMJ of Cho/+ mice:  
 
 
Figure 1: showing the Cho/+ Knee and TMJ-OA mouse model comparing mouse injected 
with Adv-RFP-LOXL2 and mouse injected with Adv-RFP-Empty  
 
 
 
 
To evaluate if LOXL2 induces anabolic responses in mouse Knee and TMJ progressive 
OA, we compared Cho/+ mice injected with Adv-RFP-LOXL2 to mice injected with Adv-
RFP-Empty. In the experimental design (Figure 1), equal numbers of male and female 
Cho/+ mice were injected intraperitoneally with either Adv-RFP-Empty or Adv-RFP-
LOXL2 bi-weekly for 12 weeks. Then the mice were sacrificed, mRNA was extracted by 
grinding the TMJ from the respective groups, TRIzol and RNAeasy kit as described in 
material and methods section. 
	13 
 
 
Differential regulation of OA- related genes by LOXL2 in Cho/+ mice TMJ OA 
cartilage: 
 
                                                                 
  
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
The group injected with Adv-RFP-LOXL2 showed higher expression of LOXL2 in both 
males and females compared to respective controls injected with Adv-RFP-Empty (Figure 
2). We identified statistically significant differences in gene expression in males and 
females and overall differences in all four groups (Figure 2). 
   
	
Figure 2: statistically significant higher expression of LOXL2 in both males and females 
injected with Adv-RFP-LOXL2 compared to those injected with Adv-RFP-Empty (TMJ 
samples). (* *  P<0.01  and * *  * P<0.001; ANOVA) 
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RT-qPCR analysis showed that forced expression of LOXL2 significantly increased the 
mRNA levels of anabolic genes Acan and Sox9 in female and male mice. The comparative 
effects were higher in female mice (Figure 3). This indicate that LOXL2 promotes 
anabolism in general. 
 
 
Figure 3: Forced expression of LOXL2 in TMJ samples significantly increased the 
mRNA levels of anabolic genes Acan and Sox9. (* *  P<0.01  and * *  * P<0.001; ANOVA) 
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Moreover, forced expression of LOXL2 showed a statistically significant increase in 
mRNA levels of Col2a1 and Runx2 genes. This increase was mentioned in both male and 
female mice, but the comparative effects were higher in female mice (Figure 4). This also 
indicates that LOXL2 promotes anabolism. 
 
 
 
Figure 4: Forced expression of LOXL2 in TMJ samples significantly increased the mRNA 
levels of anabolic genes Col2a1 and Runx2. (* P<0.05, * *  P<0.01  and * *  * P<0.001; ANOVA) 
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On the other hand,The increase in Rankl expression was not significant (“ns”) in Adv-
RFP-LOXL2-injected males or females compared to Adv-RFP-Empty controls (Figure 
5).  
 
             
 
 
 
 
 
 
Figure 5: Forced expression of LOXL2 in TMJ samples with no significant effect on mRNA levels of 
Rankl gene in both males and females mice. (* P<0.05, * *  P<0.01  and * *  * P<0.001; ANOVA) 
Figure 6: Forced expression of LOXL2 in TMJ samples significantly increase mRNA 
levels of vegf-b in female mice only. (* P<0.05, * *  P<0.01  and * *  * P<0.001; ANOVA) 
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Interestingly, as shown in Figure 6, there were statistically significant differences in 
VEGF-B gene expression between Adv-RFP-LOXL2- Adv-RFP-Empty injected mice in 
females only. MMP13 and VEGF-B gene expression in males injected with Adv-RFP-
LOXL2 was not significantly different compared to those injected with Adv-RFP-Empty. 
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Differential regulation of OA- related genes by LOXL2 in Cho/+ mice Knee OA 
cartilage: 
 
                               
                                 
 
                                   
 
 
Figure 7: Statistically significant higher expression of LOXL2 in females injected with Adv-RFP-
LOXL2 compared to those injected with Adv-RFP-Empty (knee samples). (* P<0.05, * *  P<0.01  
and * *  * P<0.001; ANOVA) 
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The group injected with Adv-RFP-LOXL2 showed higher expression of LOXL2 in females 
compared to respective controls injected with Adv-RFP-Empty (Figure 7). We identified 
statistically significant differences in gene expression in females and overall differences in 
all four groups (Figure 7). 
 
 
 
  
Figure 8: Forced expression of LOXL2 in knee samples significantly increased the mRNA 
levels of anabolic genes Acan and Sox9. (* P<0.05, * *  P<0.01  and * *  * P<0.001; ANOVA) 
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RT-qPCR analysis showed that forced expression of LOXL2 significantly increased the 
mRNA levels of anabolic genes Acan and Sox9 in female and male mice. The 
comparative effects were higher in female mice (Figure 8). This indicates that LOXL2 
promotes anabolism in general. 
 
 
  
Figure 9: Forced expression of LOXL2 in knee samples significantly increased the mRNA 
levels of anabolic genes Col2a1 and Runx2. (* P<0.05, * *  P<0.01  and * *  * P<0.001; ANOVA) 
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Moreover, forced expression of LOXL2 showed a statistically significant increase in 
mRNA levels of Col2a1 and Runx2 genes. This increase was mentioned in both male and 
female mice, but the comparative effects were higher in female mice (Figure 9). This also 
indicates that LOXL2 promotes anabolism. 
 
                              
 
 
 
 
On the other hand, the increase in Rankl expression was not significant (“ns”) in Adv-
RFP-LOXL2-injected males or females compared to Adv-RFP-Empty controls (Figure 
10).  
Figure 10: Forced expression of LOXL2 in knee samples with no significant effect on mRNA 
levels of Rankl gene in both males and females mice. (* P<0.05, * *  P<0.01  and * *  * P<0.001; 
ANOVA) 
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It was found (Figure 11) that there were no statistically significant differences in MMP13 
and VEGF-B gene expression between Adv-RFP-LOXL2- Adv-RFP-Empty injected 
mice in both male and female mouse groups. Even though in TMJ samples there were 
statistically significant differences in VEGF-B gene expression between Adv-RFP-
LOXL2- Adv-RFP-Empty injected mice in females only. 
 
 
 
 
 
 
 
 
 
Figure 11: Forced expression of LOXL2 in knee samples with no significant effect on mRNA 
levels of Vegf-b and Mmp13 genes in both males and females mice. (* P<0.05, * *  P<0.01  and * 
*  * P<0.001; ANOVA) 	
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Comparison of LOXL2 expression with TGF-β1, TNF-α and IL-1β:  
 
Next, to evaluate if LOXL2 expression occurred in degenerative lesions in human clinical 
TMJ-OA, immunofluorescence and confocal image analysis were performed.  
 
 
 
 
 
 
 
Figure 12 showed the magnified degenerative cartilage of human TMJ-OA sample. This 
degenerative region was isolated from TMJ condylar cartilage affected with OA. 
Figure 12: TMJ-OA degenerative cartilage showing LOXL2 and TGF-β1 expression 	
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Immunoflouresence analysis showed that LOXL2 expression was detected in the 
degenerative region as well as TGF-β.  
3D-reconstructed confocal Z-stacks showed that TGF-β1 was expressed in the same 
layers as LOXL2 (Figure 12). 
 
 
 
 
                
 
 
 
Figure 13: TMJ-OA degenerative cartilage showing LOXL2 and IL-1β expression 	
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Figure 13 showed the magnified degenerative cartilage of human TMJ-OA sample. This 
degenerative region was isolated from TMJ condylar cartilage affected with OA. LOXL2 
expression was detected in the degenerative region as well as IL-1β.  
3D-reconstructed confocal Z-stacks showed that IL-1β was expressed in different layers 
from LOXL2 (Figure 13). 
 
  
Figure 14: TMJ-OA degenerative cartilage showing LOXL2 and TNF-α expression 	
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Figure 14 showed the magnified degenerative cartilage of human TMJ-OA sample. This 
degenerative region was isolated from TMJ condylar cartilage affected with OA. LOXL2 
expression was detected in the degenerative region as well as TNF-α.  
3D-reconstructed confocal Z-stacks showed that TNF-α was expressed in different layers 
from LOXL2. Thus, differential expression of LOXL2 with TGF-β1, compared to TNF-α 
and IL-1β, and the associated degenerative changes in clinical specimens could have 
functional significance in TMJ-OA (Figure 14). 
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Safranin O staining was done on TMJ joints isolated from Cho/+ mice injected with 
LOXL2 and empty. Cartilage layer labeled with C and bone labeled with B. Safranin O 
staining showed the higher intensity of the stain in joints injected with LOXL2 compared 
to fewer amounts of the stain in joints injected with empty knowing that Safranin O 
staining is proportional to the proteoglycan content in the cartilage tissue. This indicates 
that LOXL2 promotes anabolism superficial layer of articular cartilage (Figure 15).   
Figure 15: Safranin-O/ Fast green staining of TMJ condylar cartilage showing the 
anabolic effect of LOXL2 in mice injected with Adv-RFP-LOXL2. C: cartilage , B: 
Bone 
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Safranin O staining was done on knee joints isolated from Cho/+ mice injected with 
LOXL2 and empty. Cartilage layer labeled with C and bone labeled with B. Safranin O 
staining showed the higher intensity of the stain in joints injected with LOXL2 compared 
to lower amounts of the stain in joints injected with empty vector (Figure 16).  Safranin O 
staining is proportional to the proteoglycan content in the cartilage tissue. This indicates 
that LOXL2 promotes anabolism in general. 
 	
Figure 16: Safranin-O/ Fast green staining of knee cartilage showing the anabolic 
effect of LOXL2 in mice injected with Adv-RFP-LOXL2. C: cartilage, B: bone  	
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DISCUSSION 
Gene therapy approaches using adenovirus and lentivirus by direct intra-articular joint 
and intraperitoneal injections have been used extensively in preclinical and clinical 
studies.[13] Adenovirus-mediated administration of bFGF, IL-1Ra, or IGF-1 was effective 
in a rat OA model.[15] Although LOXL2 has intracellular and extracellular functions, our 
goal was to evaluate if an injection of adenovirus-LOXL2 could induce protective and an 
anabolic response in the knee and TMJ cartilage. 
Since knee and TMJ-OA is a progressive disease, we chose the Cho/+ mouse model, 
which shows progressive OA-associated changes[12]: 1) at age 6 months, loss of 
proteoglycan staining at the superficial zones; 2) at 9 months, the proteoglycan staining-
deficient region extends from the superficial to the deep layers; and 3) by 15 months of 
age, typical OA-like joints, including loss of articular cartilage, misshapen meniscus, and 
inflammation in the synovial tissues, compared to wild-type (WT) littermates. Thus, 
Cho/+ mice provide an ideal model for evaluating how LOXL2 extracellular and 
intracellular functions may protect against OA. Our data show that LOXL2 induces 
anabolic responses in the knee and TMJ condylar cartilage with progressive OA. 
Interestingly, LOXL2 treatments produced anabolic responses in male and female mice 
and demonstrated that LOXL2 could be effective in attenuating OA-related changes in 
female mice. LOXL2-induced collagen cross-linking enhances the tensile strength of 
articular cartilage and resistance to collagen proteolysis.[16] During OA, collagen cross-
linking is reduced, making the ECM more susceptible to degradation by collagenases and 
aggrecanases such as ADAMTS4/5 and MMP13, which are the major proteinases that 
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degrade proteoglycans and collagens, respectively, leading to pathological changes in OA 
cartilage. Thus, LOXL2 could attenuate the adverse effects in the knee and TMJ-OA 
cartilage. 
LOXL2 is not an oncogene, but is a naturally acting enzyme in the ECM. ECM 
remodeling is crucial for the development of normal organs, whereas dysregulation of 
ECM depends on increased LOXL2 expression and contributes to several pathological 
conditions, such as fibrosis and invasive cancer.[17-19] Moreover, studies have shown that 
extracellular and nuclear LOXL2 have different functions.[20] We showed that 
recombinant LOXL2 or Adv-LOXL2 does not induce proliferation but only induces 
differentiation in osteoarthritic chondrocytes.[21] LOXL2 protein has cysteine-rich 
scavenger receptor domains, enzymatic domains and other functional domains, which 
could have a specific role in OA, and this study suggests that specific domains should be 
the focus for the development of LOXL2-derived OA therapeutics. FGF18 and BMP7 are 
in phase 1 clinical trials for OA. FGF18 has also been shown to promote colorectal 
cancer.[22] BMP7 increases breast cancer proliferation, migration, and invasion.[23] 
Similar to FGF18 and BMP7, LOXL2 is not an oncogene. Taken together, intermittent 
administration of LOXL2 and nuclear LOXL2 function in OA shows that LOXL2 could 
be used as a regenerative cartilage therapy in OA. 
mRNA levels of anabolic genes Acan and Sox9 increased significantly in both female and 
male mice by the forced expression of LOXL2 in our Cho/+ mice model. It is known that 
Acan is a major proteoglycan in the articular cartilage. This molecule is important in the 
proper functioning of articular cartilage because it provides a hydrated gel structure that 
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provides the cartilage with load-bearing properties. On the other hand, Sox9 protein 
attaches to specific regions of DNA and regulates the activity of other genes, particularly 
those that control skeletal development. Thus, it is important for the development of the 
skeleton in general. Moreover, Runx2 which is a key transcription factor associated with 
osteoblast differentiation and Col2qa1, which encodes type 2 were also increased 
significantly by the forced expression of LOXL2. This showed that LOXL2 could be 
effective in attenuating OA-related changes and that LOXL2 could have an anabolic 
effect in OA treatment. 
LOXL2 regulates aggrecan expression in Cho/+ mice which may be critical for formation 
of the proteoglycan networks and normal joint homeostasis. Whether defective LOXL2 
function leads to knee or TMJ-OA has not been evaluated. Altered ECM-related proteins 
have the propensity to develop OA. For example, in TMJ-OA, collagen crosslinking is 
defective, and collagen is more susceptible to degradation[24], and a single point mutation 
in Col11a1, as seen in Cho/+ mice[12], or Col2a1[25] leads to OA. Intracellular roles of 
LOXL2 in molecular signaling and epigenetic modification may also affect the 
development of OA. 
Further adenovirus gene therapy-based applications are in clinical development and 
approved for OA.[13] Although injection of LOXL2 increased the expression of aggrecan, 
safranin-O staining and other anabolic effects were characterized to provide mechanistic 
clues. However, the detailed understanding of molecular mechanisms by which LOXL2 
exerts its anabolic effects will be investigated in the future. .  
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Taken together, since the goal here was to evaluate if an injection of adenovirus-LOXL2 
could induce an anabolic and protective response in the TMJ and knee joint, LOXL2 was 
assessed in multiple ways using both knee and TMJ. The Cho/+ OA mouse develops 
progressive OA-associated changes with age; this model allowed us to determine that 
LOXL2 has a beneficial effect in blocking the progression of OA. Next, 
immunofluorescence and confocal image analysis in degenerative lesions in human 
clinical TMJ-OA showed that TGF-β1 was expressed in the same layers as LOXL2. 
Using a combination of various tools and models, we showed that LOXL2 delivered by 
adenovirus in vivo produces both chondroprotective and anabolic effects in knee and 
TMJ. These data have therapeutic implications as to the potential efficacy of mediators of 
LOXL2 in treating knee and TMJ-OA. 
	
 
 
 
 
 
 
 	  
	33 
 
 
CONCLUSION 
In conclusion, this study shows that LOXL2 has a beneficial effect in blocking the 
progression of OA and induces anabolic and chondroprotective effects in knee and TMJ. 
However, the detailed understanding of molecular mechanisms by which LOXL2 exerts 
its anabolic effects needs to be investigated in the future.  
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